Paul is a Managing Director responsible for Business Development for ICR Westwicke. He is involved in the origination of new business opportunities in Healthcare Investor Relations and Public Relations, as well as outreach with private equity and venture capital firms focused on Healthcare.
He joined the firm following a 30-year career on Wall Street focused on Capital Markets and Corporate Finance. He previously held senior positions at Deutsche Bank, HSBC and JPMorgan Chase. Paul’s investment banking background provides important perspective on the critical role effective marketing and investor communications can have on valuation and positioning with investors. He has originated and structured a wide variety of transactions for companies raising growth capital across the public and private markets in the U.S., Europe and Asia.
He received a B.A. in Politics from The Catholic University of America and an M.B.A. in Finance from the Gabelli School of Business at Fordham University.
Michael leads ICR’s U.S. Healthcare Public Relations practice. Michael has experience across numerous therapeutic areas, including oncology, rare disease, metabolic disease, infectious disease/vaccines, gene therapy, neuroscience, mental health, cardiovascular, health tech, and autoimmune, among others. He’s led product communications programs ranging from early stage to product launch and beyond. Michael’s client experience includes: AstraZeneca, BMS, Pfizer, Pfizer Animal Health (now Zoetis), Teva, REGENXBIO, Sanofi/Genzyme, Intuitive Surgical, AARP, American Liver Foundation, American Association of Clinical Endocrinologists, NIH, ACOG, and NAMI.
Passionate about translating science and innovation to affect behavior change, Michael and his teams have earned more than 140 industry awards. Michael was nominated as the Most Purposeful Agency Pro for the inaugural PRWeek Purpose Awards.
Prior to joining ICR/Westwicke, Michael served as Vice President of Corporate Communications at the University of Maryland Medical System, as the Managing Director at JPA Health, and as the Global Head of Corporate Communications for MedImmune (biologics arm of AstraZeneca), among other healthcare agency and in-house positions.
Most recently, he has acted as an independent consultant to healthcare companies on investor relations and corporate strategy matters.
Previously, Aman worked for Systematic Financial Management (AMG) for 17 years, beginning as a research analyst and ultimately as a portfolio manager of a multi-billion dollar long-only fund. Aman began his career on the sell-side working at UBS and Prudential Securities covering medical devices and biotechnology, respectively. His coverage included Celgene, Biogen, Gilead Sciences, Boston Scientific, Medtronic, and Zimmer among others.
At ICR Westwicke, Aman is focused on advising companies in the healthcare industry, concentrating his efforts in the medical technology/diagnostics and life sciences sectors. As a senior member of the team, Aman actively engages with both private and public clients in capital markets advisory and strategic investor relations, leveraging his strong relationships in the sector and investment expertise.
Aman received an MBA in Finance from Carnegie Mellon University and a BA in Molecular Biology from Rutgers University. He is also a CFA charterholder. Aman lives in New Jersey with his wife and three children.
Kate has experience across many therapeutic categories including oncology (including I-O), hematology, dermatology, pain, digital health, device, EMR, auto-immune, cardiology and rare diseases and has managed products along the spectrum of the drug life cycle and clinical trial stages. Kate’s client experience includes Incyte, Novartis, Intercept, Pfizer, Cancer Research Institute, Alexion Pharmaceuticals and Medidata.
Passionate about advocacy and third-party impact, she has also served on the New York City Regional Board of Directors for the American Heart Association and founded the Young Professionals of the American Heart Association.
Prior to joining ICR, Kate served as an EVP at Weber Shandwick, as a Group Director at W2O Group and as a Group Vice President at Makovsky + Co. Kate graduated with honors earning her B.A. in Communications from the University of Pennsylvania where she studied healthcare communications at the Annenberg School of Communications.
Mark’s career as a communications strategist and practitioner spans both coasts and includes developing and executing award-winning corporate communications and investor relations programs for clients in all stages of growth, from pre-IPO to commercial phase publicly-traded companies. He previously served in senior-level positions at two top ten U.S. healthcare agencies, including leading West Coast firm Canale Communications.
Specializing in corporate and product communications, investor relations, content development, issues management and crisis communications, Mark has provided these services to biopharmaceutical and medical device companies across diverse treatment areas, including precision oncology, immunotherapy and rare disease. At the same time, he provides strategic corporate level counsel to C-level executives and collaborates with staff throughout organizations to ensure consistency and clarity in all communications.
As a corporate staff professional, Mark served in communications and public relations positions for an emerging biotech firm and international pharmaceutical company, and operated his own boutique agency in San Diego for many years.
He developed his expertise in helping companies shape their messages to the investment community through 20 years working on Wall Street in a variety of healthcare research and client-facing roles.
Immediately prior to joining ICR Westwicke, Mike was a Managing Director at Advent Capital Management covering institutional investors and consultants in multiple verticals and geographies. Prior to that, he held business development and client service roles at Boston-area investment management firms including State Street, as well as healthcare research and research sales roles at Standard & Poor’s, Salomon Brothers, Lazard, and Bear Stearns. His diversified experiences have provided an intimate knowledge of the public and private investment markets from multiple viewpoints, as well as significant industry relationships. Mike has a BA in economics from Trinity College (CT) and an MBA in finance from Vanderbilt University. He lives in Sudbury, Massachusetts, with his wife and three sons.
Previously, Lyndon was Head of Global Corporate Governance at Dimensional Fund Advisors where he oversaw and implemented the firm’s global stewardship and ESG initiatives. Prior to Dimensional, Lyndon was Partner and Head of Governance & Listing Standards at EQX, a capital markets start-up. Lyndon began his career in governance at BlackRock by supporting BlackRock’s board of directors on intra-company governance matters, before serving as one of BlackRock Investment Stewardship team’s lead governance analysts overseeing portfolio companies representing around $450B of BlackRock’s AUM.
As a recognized thought leader in ESG and shareholder activism, Lyndon frequently participates on panels and his perspectives have been published or quoted in leading media outlets (WSJ, Financial Times).
Lyndon received his B.A., magna cum laude, from Columbia University.
Stephanie invests the resources to be well versed in each healthcare client’s corporate strategy and competitive position in order to develop customized programs to raise visibility for their differentiated science, lead candidates, clinical development pathway and commercialization strategy. She is well versed in partnering with privately companies to raise their profiles across targeted VC and crossover audiences, and navigate the transition to public ownership. Throughout her career, Stephanie has represented biotechnology and specialty pharmaceutical companies from a wide range therapeutic areas spanning such areas as oncology, central nervous system, respiratory, infectious disease, dermatology, pain management, ophthalmology, and cardiology.
Prior to joining ICR, Stephanie held position in the investor relations field with increasing levels of responsibility as a Senior Vice President of Investor Relations at The Ruth Group, an Assistant Vice President Morgen-Walke Associates, and a Senior Associate at The Financial Relations Board. Earlier, Stephanie held positions at Alliance Capital Management, Bankers Trust and the Federal Reserve Bank of New York. She earned a BA in Economics and International Relations from Smith College and an MBA in Finance and International Business from New York University’s Stern School of Business.
Read Stephanie’s article: If You Want to Raise Money, Raise Your Visibility
Patti Bank joined ICR Westwicke in 2015 as a Managing Director, leading our San Francisco effort in Life Sciences. Patti’s focus is working with both public and private companies in the specialty pharma/pharma and biotechnology areas. Her analytical expertise and strong healthcare industry relationships stem from more than 25 years working in the life sciences field, including 20 years as a sell-side analyst and more than five years of industry experience as a senior pharmaceutical medical representative.
Patti worked on Wall Street for over 20 years as a sell-side equity analyst primarily responsible for covering the pharmaceutical and specialty pharmaceutical sectors. During that time, she developed a thorough knowledge of financial analysis, business development, strategic planning and capital markets. Patti has an extensive industry network at the senior management level.
Most recently, Patti was a Managing Director at Discern Analytics. There, she was a founding member of the healthcare team. Her responsibilities included developing a big data analytics platform by monitoring unique data sources uncovering information that could be mapped to spot early investment trends impacting specialty pharmaceutical stocks. Prior to Discern, Patti was a Senior Vice President at Pacific Growth Equities (acquired by Wedbush) and Vector Securities (acquired by Prudential), both research and strategic advisory firms focusing on small-to-mid capitalization healthcare companies. Over the years, she has participated in numerous initial public offerings, capital raises and M&A transactions. Patti has covered companies in multiple therapeutic fields including GI, pain management, diabetes, respiratory, dermatology and CNS.
Patti earned an MBA from Drexel University and a BA in Neurobiology and Economics from Rutgers University. She lives in Virginia with her husband and four children.
Read blog posts by Patti Bank >>
Prior to joining ICR Westwicke, Peter spent six years as Director or Senior Director of Investor Relations with two biotechnology companies, MedImmune and Human Genome Sciences. In addition, he was Vice President, Investor Relations at Catalyst Health Solutions, a pharmacy benefit manager, and most recently Director, Global Investor Relations with Qiagen, a life sciences company based in Germany. Peter’s investor relations responsibilities included communicating strategic and financial initiatives directly with the investment community, creating and maintaining relationships with institutional investors and analysts, and targeting prospective shareholders to broaden investment interest.
Peter started his Wall Street career as a sell-side analyst. He was an equity research analyst with Unterberg Harris in New York, and became a Senior Equity Securities Analyst with Interstate/Johnson Lane and Wachovia Services in Charlotte, North Carolina.
Peter earned a BS in Chemistry and an MBA in Finance/Accounting, both from the University of Connecticut. He lives in Montgomery County, Maryland, with his wife and two children.
Read blog posts by Peter Vozzo >>